Kazia Therapeutics (KZIA) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Rallybio (RLYB) has outperformed Kazia Therapeutics (KZIA) over the past year, gaining 280.4% versus a gain of 3.6%. Over five years, RLYB leads with a -87.5% price change compared with -98.6% for KZIA. Rallybio is the larger company by market cap ($86.5 million vs $82.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | RLYB |
|---|---|---|
| Share price | $7.25 | $16.28 |
| Market cap | $82.85M | $86.49M |
| 1-day change | -2.03% | -2.95% |
| YTD return | +5.22% | +196.65% |
| 1-year return | +3.57% | +280.37% |
| 5-year return | -98.64% | -87.46% |
| P/E ratio (TTM) | — | 2.03 |
| EPS (TTM) | $-6.85 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $858.00K |
| Revenue growth (YoY) | — | +34.91% |
| Net income (latest FY) | — | $-8.98M |
| Operating margin | — | -3853.61% |
| Net margin | — | -1046.39% |
| 52-week high | $17.40 | $17.57 |
| 52-week low | $4.86 | $3.67 |
| Distance from 52-week high | -58.33% | -7.36% |
| Analyst consensus | none | — |
| Avg. price target upside | +290.90% | — |
| Average volume | 277.70K | 15.38K |
| Shares outstanding | 11.43M | 5.31M |
| Employees | 6 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed KZIA by 276.8 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
KZIA vs RLYB FAQ
Which is bigger, Kazia Therapeutics or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $86.49M compared with $82.85M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, KZIA or RLYB?
RLYB returned +280.37% over the past 12 months, compared with +3.57% for KZIA (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.